Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Palisade Bio (PALI) will feature PALI-2108 clinical and translational findings in four presentations at UEG Week 2026.
An oral presentation will cover Phase 1b findings in fibrostenotic Crohn’s disease, including early endoscopic improvement and evidence of PDE4 target engagement. Three moderated posters will address gut-targeted drug exposure and safety and tolerability in inflammatory bowel disease, clinical response in ulcerative colitis within one week of treatment, and a biomarker being prospectively validated to predict treatment response in ulcerative colitis.
The conference runs October 17–20 in Barcelona. PALI-2108 is a once-daily oral treatment candidate being advanced into Phase 2 development in ulcerative colitis and Crohn’s disease. The announcement provides no patient counts or numerical efficacy results.
Positive
- Phase 1b Crohn’s disease findings include early endoscopic improvement and evidence of PDE4 target engagement.
- Ulcerative colitis response within one week of treatment will be covered in a poster.
- Gut-targeted drug exposure will be featured in an inflammatory bowel disease poster.
- Palisade describes safety and tolerability in inflammatory bowel disease as favorable.
- Phase 2 development is being advanced in ulcerative colitis and Crohn’s disease.
Negative
- Clinical findings are presented without patient counts or numerical efficacy results.
- Response-prediction biomarker is still being prospectively validated in ulcerative colitis.
Details
Market move: PALI +3.45% in the Sep 28 session. PALI-2108 clinical data presentation
On Sep 28, the day this news came out, PALI closed 3.45% above the previous close. Our momentum scanner recorded 13 alerts for this stock that day. That session’s volume was 2.6x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Sep 28 session.
Key Terms
pde4 technical
pharmacokinetics medical
fibrostenotic medical
cAMP technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Oral presentation to highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn’s disease
Three moderated posters to showcase gut-targeted exposure, favorable safety and tolerability, rapid clinical response in ulcerative colitis, and the development of a biomarker to predict treatment response
Denver, CO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that its lead program, PALI-2108, will be featured in four presentations at United European Gastroenterology (UEG) Week 2026. The presentations include an oral presentation of Phase 1b findings in fibrostenotic Crohn’s disease and three moderated posters. The conference will take place October 17–20, 2026, in Barcelona, Spain.
The presentations will highlight early clinical activity in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD), gut-targeted exposure and differentiated pharmacokinetics, and favorable safety and tolerability. They will also feature a mechanistically anchored transcriptomic biomarker being prospectively validated to help predict treatment response in UC. Together, these provide additional clinical and translational support for the continued development of PALI-2108 as a once-daily oral treatment for inflammatory bowel disease. PALI-2108 is currently being advanced into Phase 2 clinical development in both UC and CD.
Presentation details are as follows:
Session Type: Oral Presentation
Title: Gut-Targeted PDE4 Inhibition with Once-Daily PALI-2108 Demonstrates Early Clinical and Biomarker Improvements in Fibrostenotic Crohn’s Disease: Results from a Phase 1b Study
Presenter: Florian Rieder, MD, Associate Staff, Department of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic
Presentation Number: OP003
Session Date & Time: Sunday, October 18, 2026 from 3:40 PM to 3:50 PM CEST
Location: Room B3
Session Type: Moderated Poster Presentation
Title: PALI-2108, a Novel, Next-Generation Oral Once-Daily PDE4 Inhibitor Exhibits Gut-Targeted Drug Exposure and Favorable Safety and Tolerability in Inflammatory Bowel Disease
Presenter: Mitchell Jones, M.D., Ph.D., President and Chief Medical Officer
Presentation Number: MP0564
Session Date & Time: Monday, October 19, 2026 from 1:24 PM to 1:30 PM CEST
Location: Hall 7 – Poster Stage 1
Session Type: Moderated Poster Presentation
Title: PALI-2108, a New GI-Activated PDE4 Inhibitor Promotes Clinical Response in UC Patients Within One Week of Treatment
Presenter: James Izanec, MD, AGAF, VP, Head of Clinical Development
Presentation Number: MP0844
Session Date & Time: Tuesday, October 20, 2026 from 10:30 AM to 10:36 AM CEST
Location: Hall 7 – Poster Stage 2
Session Type: Moderated Poster Presentation
Title: Development of a Mechanistically Anchored PDE4/cAMP Transcriptomic Biomarker to Predict Response to PALI-2108 in Ulcerative Colitis
Presenter: Mitchell Jones, M.D., Ph.D., President and Chief Medical Officer
Presentation Number: MP0845
Session Date & Time: Tuesday, October 20, 2026 from 10:36 AM to 10:42 AM CEST
Location: Hall 7 – Poster Stage 2
UEG Week is one of the world’s leading forums for gastroenterology, bringing together clinicians, researchers and industry leaders to present and discuss advances in the understanding and treatment of gastrointestinal diseases. For more information about UEG Week, please visit the conference website.
About PALI-2108
PALI-2108 is an oral, locally activated PDE4 inhibitor prodrug designed for once-daily dosing and targeted bioactivation in the terminal ileum and colon. Across Phase 1 studies in healthy volunteers and patients with ulcerative colitis and fibrostenotic Crohn’s disease, PALI-2108 demonstrated favorable safety and tolerability, differentiated pharmacokinetics and exposures supportive of sustained PDE4 inhibition, supporting continued advancement in Phase 2 clinical trials.
About Palisade Bio
Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company developing prodrugs for patients living with inflammatory and fibrotic diseases.
The Company’s lead clinical product candidate, PALI-2108, is being advanced into Phase 2 clinical trials as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). Despite the availability of multiple biologic and small-molecule therapies, many patients with UC and CD do not achieve durable remission, lose response over time, or discontinue treatment because of safety or tolerability limitations. The Company believes PALI-2108 has the potential to address these limitations through once-daily oral dosing, targeted lower-intestinal bioactivation and broad PDE4-mediated anti-inflammatory activity.
For more information, please go to www.palisadebio.com.
Forward Looking Statements
Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: implied or express statements regarding the pharmacological properties, safety, tolerability, clinical response and efficacy, and therapeutic potential of PALI-2108, dosing levels and timing of key PALI-2108 development milestones such as regulatory submissions and approvals, trial enrollments and commencements and efficacy readouts, and the Company’s expected cash runway. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the Company’s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, clinical response and efficacy, dosing or durability of effect, observed from preclinical or clinical trials (such as our Phase 1b findings) with a limited number of patients, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2026, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What PALI-2108 findings will Palisade Bio present at UEG Week 2026?
The presentations will cover early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn’s disease, plus clinical response in ulcerative colitis within one week of treatment. Posters will also address gut-targeted exposure and safety and tolerability. The announcement gives no patient counts or numerical efficacy results.